SM
Sabby Management Portfolio holdings
AUM
$13M
This Quarter Return
-4.91%
1 Year Return
-26.95%
3 Year Return
-56.43%
5 Year Return
-61.92%
10 Year Return
-71.17%
AUM
$497M
AUM Growth
+$497M
(+66%)
Cap. Flow
-$12.7M
Cap. Flow
% of AUM
-2.55%
Top 10 Holdings %
Top 10 Hldgs %
59.18%
Holding
270
New
59
Increased
53
Reduced
43
Closed
46
Top Buys
| 1 |
SPDR S&P 500 ETF Trust
SPY
|
$22.4M |
| 2 |
Amgen
AMGN
|
$21.5M |
| 3 |
Regeneron Pharmaceuticals
REGN
|
$14.1M |
| 4 |
Sarepta Therapeutics
SRPT
|
$9.88M |
| 5 |
Biogen
BIIB
|
$9.65M |
Top Sells
| 1 |
iShares Russell 2000 ETF
IWM
|
$33.1M |
| 2 |
CRDC
CARDICA INC COM NEW (DE)
CRDC
|
$28.7M |
| 3 |
Plus Therapeutics
PSTV
|
$19.3M |
| 4 |
WINT
Windtree Therapeutics Inc
WINT
|
$11.2M |
| 5 |
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
|
$9.8M |
Sector Composition
| 1 | Healthcare | 48.01% |
| 2 | Consumer Staples | 0.23% |
| 3 | Technology | 0.19% |
| 4 | Industrials | 0.18% |
| 5 | Communication Services | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
IMMU
1
DELISTED
Immunomedics Inc
IMMU
| – | – | 0 | – | – |
|
|
2
SPDR S&P 500 ETF Trust
SPY
$658B
| $22.4M | 1.12% | +108,899 | New | +$22.4M |
|
|
3
Amgen
AMGN
$155B
| $21.5M | 1.08% | +143,486 | New | +$21.5M |
|
|
4
Plus Therapeutics
PSTV
$45.3M
| $14.3M | 0.72% | 7,305,690 -9,844,607 | -57% | -$19.3M |
|
|
5
Regeneron Pharmaceuticals
REGN
$61.5B
| $14.1M | 0.7% | +39,027 | New | +$14.1M |
|
|
6
Sarepta Therapeutics
SRPT
$1.78B
| $9.88M | 0.49% | +505,937 | New | +$9.88M |
|
|
7
Biogen
BIIB
$19.4B
| $9.65M | 0.48% | +37,077 | New | +$9.65M |
|
8
Tenax Therapeutics
TENX
$27.3M
| $5.68M | 0.28% | 2,771,109 +77,572 | +3% | +$159K |
|
9
Arbutus Biopharma
ABUS
$711M
| $4.95M | 0.25% | 1,197,338 +197,338 | +20% | +$815K |
|
|
NWBO
10
DELISTED
Northwest Biotherapeutics, Inc. Common stock
NWBO
| $4.84M | 0.24% | 3,317,519 +2,399,577 | +261% | +$3.5M |
|
11
Eledon Pharmaceuticals
ELDN
$155M
| $4.56M | 0.23% | +812,200 | New | +$4.56M |
|
|
IRD
12
Opus Genetics, Inc. Common Stock
IRD
$73.1M
| $4.36M | 0.22% | +13,212,254 | New | +$4.36M |
|
|
EIGR
13
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
| $4.35M | 0.22% | +259,643 | New | +$4.35M |
|
14
Dynavax Technologies
DVAX
$1.19B
| $4.23M | 0.21% | 220,000 +100,000 | +83% | +$1.92M |
|
|
ALXN
15
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $3.88M | 0.19% | 27,856 +25,900 | +1,324% | +$3.61M |
|
16
Precigen
PGEN
$1.34B
| $3.79M | 0.19% | 111,907 +100,912 | +918% | +$3.42M |
|
|
NVIV
17
DELISTED
InVivo Therapeutics Holdings Corp
NVIV
| $3.79M | 0.19% | +542,500 | New | +$3.79M |
|
|
VXZ
18
DELISTED
iPath S&P 500 VIX Mid-Term Futures ETN due 1/30/2019
VXZ
| $3.26M | 0.16% | 300,000 -225,132 | -43% | -$2.45M |
|
19
Regenxbio
RGNX
$451M
| $3.24M | 0.16% | 300,329 +183,469 | +157% | +$1.98M |
|
|
SAGE
20
DELISTED
Sage Therapeutics
SAGE
| $3.21M | 0.16% | 100,000 +91,877 | +1,131% | +$2.95M |
|
21
Indaptus Therapeutics
INDP
$7.19M
| $2.95M | 0.15% | 714,062 +43,613 | +7% | +$180K |
|
|
PRTK
22
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
| $2.92M | 0.15% | 192,322 +69,709 | +57% | +$1.06M |
|
|
ADMS
23
DELISTED
Adamas Pharmaceuticals, Inc.
ADMS
| $2.89M | 0.14% | +199,890 | New | +$2.89M |
|
|
ESRX
24
DELISTED
Express Scripts Holding Company
ESRX
| $2.84M | 0.14% | +41,311 | New | +$2.84M |
|
|
ONCS
25
DELISTED
OncoSec Medical Incorporated
ONCS
| $2.83M | 0.14% | 1,111,348 -113,011 | -9% | -$288K |
|